Financial Personal
Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing led by 3E Bioventures Capital and Proxima Ventures
BALTIMORE, June 20, 2024 (GLOBE NEWSWIRE) -- Read More
Related
Share this page
Guest Posts by Easy Branches